MTOR and central nervous system cancer: With respect to the PI3K/AKT/mTOR pathway, the dual PI3K/mTOR inhibitor dactolisib attenuated tumor progression in animal models of glioma [6,7], and the allosteric AKT inhibitor MK-2206 presented antitumoral effects in vitro [8,9].